Search Results for "Prophylaxis"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Prophylaxis. Results 81 to 90 of 198 total matches.

Aspirin for Primary Prevention of Cardiovascular Disease (Revisited)

   
The Medical Letter on Drugs and Therapeutics • Jul 03, 2006  (Issue 1238)
prophylaxis in various doses for an average of 6.4 years lowered the risk of myocardial infarction in men ...
When the use of aspirin for primary prevention of cardiovascular diseases was last reviewed in The Medical Letter, only one placebo-controlled prospective trial was available: the (male) Physicians' Health Study. Last year, a second large, randomized, placebo-controlled study was reported as part of the Women's Health Study. Recently a sex-specific meta-analysis of 6 trials, including these two, was published.
Med Lett Drugs Ther. 2006 Jul 3;48(1238):53 |  Show IntroductionHide Introduction

Desirudin (Iprivask) for DVT Prevention

   
The Medical Letter on Drugs and Therapeutics • Nov 01, 2010  (Issue 1350)
following low-dose subcutaneous treatment with desirudin for thrombosis prophylaxis after hip-replacement ...
The injectable direct thrombin inhibitor desirudin (Iprivask – Canyon), a recombinant analog of hirudin, the leech anticoagulant protein, was approved by the FDA in 2003 for prevention of venous thromboembolism (VTE) after elective hip arthroplasty, but was only marketed recently in the US. It has been available in Europe as Revasc for about 10 years. Two other hirudin analogs are available in the US: lepirudin (Refludan) for treatment of heparin-induced thrombocytopenia (HIT) and bivalirudin (Angiomax) for use in percutaneous coronary intervention (PCI).
Med Lett Drugs Ther. 2010 Nov 1;52(1350):85-6 |  Show IntroductionHide Introduction

Vaccines for Travelers

   
The Medical Letter on Drugs and Therapeutics • Nov 19, 2018  (Issue 1560)
for pre-exposure prophylaxis (PrEP). The World Health Organization (WHO) recommends a 2-dose PrEP schedule ...
Persons planning to travel outside the US should be up to date on routine vaccines and, depending on their destination, duration of travel, and planned activities, may also receive certain travel-specific vaccines. Tickborne encephalitis and dengue vaccines, which are not available in the US, are reviewed in a separate article available online. Detailed advice for travel to specific destinations is available from the Centers for Disease Control and Prevention (CDC) at www.cdc.gov/travel/destinations/list. Recommendations for administration of vaccines as part of routine...
Med Lett Drugs Ther. 2018 Nov 19;60(1560):185-92 |  Show IntroductionHide Introduction

In Brief: A New Formulation of Posaconazole (Noxafil)

   
The Medical Letter on Drugs and Therapeutics • Feb 02, 2015  (Issue 1461)
drug posaconazole (Noxafil - Merck) for prophylaxis of Aspergillus and Candida infections in adults ...
The FDA has approved an IV formulation of the antifungal drug posaconazole (Noxafil - Merck) for prophylaxis of Aspergillus and Candida infections in adults at high risk for these infections, such as those with prolonged neutropenia. Posaconazole is also available as delayed-release tablets and an oral suspension.With activity against Aspergillus and Candida, posaconazole has an antifungal spectrum similar to that of voriconazole (Vfend, and generics), but unlike voriconazole it is also active against many species of Mucorales (formerly called Zygomycetes), such as Mucor and Rhizopus....
Med Lett Drugs Ther. 2015 Feb 2;57(1461):20 |  Show IntroductionHide Introduction

Antiviral Drugs

   
Treatment Guidelines from The Medical Letter • Mar 01, 2013  (Issue 127)
to vaccination for prophylaxis and treatment of influenza. In recent years, the susceptibility of circulating ...
The drugs of choice for treatment of viral infections (other than HIV) and their dosages are listed in Tables 1-6 on the pages that follow. Some of the indications and dosages recommended here have not been approved by the FDA. Vaccines used for the prevention of viral infections are discussed elsewhere.
Treat Guidel Med Lett. 2013 Mar;11(127):19-30 |  Show IntroductionHide Introduction

Recombinant Antihemophilic Factor

   
The Medical Letter on Drugs and Therapeutics • Jun 11, 1993  (Issue 898)
equivalent to that of plasma-derived FVIII. Recombinate used for prophylaxis or on demand for six ...
Recombinate (Baxter) and Kogenate (Miles), two recombinant-DNA-derived Factor VIII (rFVIII) preparations, were recently approved for marketing by the US Food and Drug Administration. Clotting factor concentrates are generally prepared from large plasma pools obtained from thousands of donors. Without adequate inactivation of viruses, these concentrates can transmit hepatitis B, hepatitis C, and the human immunodeficiency virus (HIV), among others. The new recombinant products, which include human albumin added as a stabilizer, are claimed to be free of blood-borne viruses.
Med Lett Drugs Ther. 1993 Jun 11;35(898):51-2 |  Show IntroductionHide Introduction

Two Neuraminidase Inhibitors for Treatment of Influenza

   
The Medical Letter on Drugs and Therapeutics • Oct 08, 1999  (Issue 1063)
. CLINICAL TRIALS — Prophylaxis − A four-week prophylactic trial during the influenza season in 1,107 adults ...
Zanamivir, a neuraminidase inhibitor taken by inhalation, has been approved by the FDA for treatment of influenza. Oseltamivir phosphate, an oral neuraminidase inhibitor, will probably be approved soon.
Med Lett Drugs Ther. 1999 Oct 8;41(1063):91-3 |  Show IntroductionHide Introduction

COVID-19 Updates

   
The Medical Letter on Drugs and Therapeutics • Mar 21, 2022  (Issue 1646)
/3K5AcNc. Accessed March 3, 2022. 2. Tixagevimab and cilgavimab (Evusheld) for pre-exposure prophylaxis ...
The CDC has issued new guidance allowing for an interval of up to 8 weeks between the first and second primary doses of an mRNA COVID-19 vaccine in certain patients 12-64 years old.1 Product labeling currently recommends a 3-week interval between the first two doses of the Pfizer/BioNTech mRNA vaccine (Comirnaty) and a 4-week interval between the first two doses of the Moderna mRNA vaccine (Spikevax). The new guidance is based on data suggesting that a longer interval can decrease the risk of myocarditis and may improve vaccine efficacy.
Med Lett Drugs Ther. 2022 Mar 21;64(1646):47-8 |  Show IntroductionHide Introduction

Expanded Table: Some Vaccines for Travelers (online only)

   
The Medical Letter on Drugs and Therapeutics • Nov 19, 2018  (Issue 1560)
days prior to vaccination ▶ Administer at least 10 days before starting antimalarial prophylaxis ...
View the Expanded Table: Some Vaccines for Travelers
Med Lett Drugs Ther. 2018 Nov 19;60(1560):e192-4 |  Show IntroductionHide Introduction

In Brief: Prevention of Meningococcal B Disease

   
The Medical Letter on Drugs and Therapeutics • Dec 09, 2013  (Issue 1431)
prophylaxis is recommended. 1. NJ Carter. Multicomponent meningococcal serogroup B vaccine (4CMenB; Bexsero ...
An outbreak (8 cases to date) of meningococcal disease at Princeton University caused by Neisseria meningitidis serogroup B has led the FDA and CDC to permit importation and investigational use (at Princeton University only) of a meningococcus B vaccine (4CMenB; Bexsero – Novartis) that has not been approved in the US. Bexsero has been approved for use in the European Union and in Australia.THE VACCINE — Until recently, no serogroup B vaccine was widely available because the polysaccharide capsule of the B serogroup, unlike those of the other main meningococcal serogroups (A, C, Y, and...
Med Lett Drugs Ther. 2013 Dec 9;55(1431):97 |  Show IntroductionHide Introduction